**Author details**

Erlinda M. Gordon1,2,3\*, Nicole L. Angel1 , Ted T. Kim1 , Don A. Brigham2 , Sant P. Chawla1 and Frederick L. Hall3

1 Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, USA

2 Aveni Foundation, Santa Monica, CA, USA

3 Delta Next-Gene, LLC, Santa Monica, CA, USA

\*Address all correspondence to: erlinda.gordon@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**23**

*Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy*

[9] Al-Shihabi A, Chawla SP, Hall FL, et al. Exploiting oncogenic drivers along the CCNG1 pathway for cancer therapy and gene therapy. Molecular Therapy - Oncolytics. 2018;11:122-126. DOI: 10.1016/j.omto.2018.11.002

[10] Chawla SP, Bruckner H, Morse MA, et al. A phase I-II study using Rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Molecular Therapy - Oncolytics. 2019;12:56-67. DOI: 10.1016/j.

[11] Sarcoma Oncology Research Center, LLC. SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB

[12] Morrison BA. Soft tissue sarcomas of the extremities. Proceedings (Baylor

immunotherapy in soft tissue sarcoma. Human Vaccines & Immunotherapeutics.

[14] Zhou M, Bui N, Bolleddu S, et al. Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. Immunotherapy. 2020;12:1303-1312. DOI: 10.2217/

[15] Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or

and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS). Clinical Trial Registration NCT03138161, clinicaltrials.gov, https:// clinicaltrials.gov/ct2/show/NCT03138161

(31 August 2020, accessed 11

University Medical Center). 2003;16:285-290. DOI:

[13] Tseng WW, Somaiah N, Engleman EG. Potential for

10.1080/08998280.2003.11927915

2015;10:3117-3124. DOI: 10.4161/

21645515.2014.983003

imt-2020-0155

January 2021)

omto.2018.12.005

*DOI: http://dx.doi.org/10.5772/intechopen.96664*

[2] Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways. American Journal of Clinical Oncology. 2016;39:98-106. DOI: 10.1097/COC.0000000000000239

[3] Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes & Development. 2018;32:1267-1284. DOI: 10.1101/

[4] Chawla SP, Sankhala KK, Ravicz J,

combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. Journal of Clinical Oncology. 2018;36:e23568 e23568. DOI: 10.1200/JCO.2018.36.15\_

et al. Clinical experience with

[5] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350-1355.

DOI: 10.1126/science.aar4060

et al. Improved survival with

10.1056/NEJMoa1003466

England Journal of Medicine. 2013;369:122-133. DOI: 10.1056/

[8] www.accessdata.fda.gov/

NEJMoa1302369

drugsatfda\_docs

[6] Hodi FS, O'Day SJ, McDermott DF,

ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. 2010;363:711-723. DOI:

[7] Wolchok JD, Kluger H, Callahan MK, et al. Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients. The New

[1] Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. European Journal of Immunology. 2017;47:765-779. DOI: 10.1002/

**References**

eji.201646875

gad.314617.118

suppl.e23568

*Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy DOI: http://dx.doi.org/10.5772/intechopen.96664*
